CRB-601 monoclonal antibody clinical trials

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

This study is testing a new drug called CRB-601, along with existing immunotherapy, for people with advanced solid tumors that haven't responded to other treatments. The aim is to check its safety, how it works in the body, and if it helps shrink tumors.